You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 152 No. 6, June 1998 TABLE OF CONTENTS
  Archives
  •  Online Features
  Special Feature
 This Article
 •Extract
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on ISI (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Genetics
 •Genetic Disorders
 •Alert me on articles by topic

Pathological Case of the Month

MAJ Mary K. Mather, MC, USA; COL Purnima Sau, MC, USA
From the Dermatology Service, Walter Reed Army Medical Center, Washington, DC.

Arch Pediatr Adolesc Med. 1998;152:603-604.

AN OTHERWISE healthy 13-month-old boy was taken to the pediatrician for evaluation of "crying when in the sun," leathery appearance of the skin on the dorsum of the hands (Figure 1), and irritation and redness of the skin of the upper lip and bridge of nose. Five months later, when the child moved from a northern climate to Georgia, the mother noted marked worsening of the redness and sun-induced sensitivity of his skin. A clinical diagnosis of erythropoietic protoporphyria (EEP) was made. Laboratory studies showed a florescence (4+) of the red blood cells. Erythrocyte protoporphyrin level was 3.96 µmol/L (normal, <0.62 µmol/L). A biopsy specimen from an affected area of skin on the right dorsal hand is shown in Figure 2.


Figure 1.


Figure 2.


Diagnosis and Discussion: Erythropoietic Protoporphyria

Figure 1. Dorsal hands of the patient, demonstrating the leathery, aged appearance.

Figure 2. Eosinophilic, homogeneous periodic acid–Schiff-positive material around blood vessels in the papillary dermis (original magnification x25).

Figure 3. Higher-power view demonstrating perivascular distribution of the periodic acid–Schiff-positive material (original magnification x50).


Figure 3.

Erythropoietic protoporphyria (EPP) is an autosomal dominant disorder of variable expressivity that usually presents between the ages of 2 and 5 years with complaints of burning, stinging, or itching of sun-exposed skin.1 There may be edematous, erythematous plaques or rare papulovesicular lesions. Chronic changes of the skin include dyspigmentation, papular thickening, or hyperkeratosis of the skin of the dorsal hands, shallow pitted or linear scars of the face (especially the nose), and linear furrows around the lips. Systemic symptoms are often absent but may include cholecystitis or cholelithiasis, hypersplenism, and rarely hepatic failure due to portal and periportal fibrosis.

The disease results from a congenital abnormality in the enzyme ferrochelatase, which is necessary for the biosynthesis of heme. The resultant accumulation of the heme precursor, protoporphyrin IX in the red blood cells, liver, bone marrow, and plasma leads to the photosensitivity and systemic symptoms described earlier. The protoporphyrin level in the serum and red blood cells is markedly elevated in patients with EPP, and diagnosis can be made by measuring the level of this protoporphyrin in the serum or erythrocytes.2 The route of elimination of protoporphyrin is via the feces; thus, one may also measure fecal protoporphyrin levels to confirm a diagnosis of EPP. The large protoporphyrin molecule is poorly soluble in water, therefore, unlike other types of porphyria, the urine porphyrin levels are normal in EPP.

Histological features of EPP are distinctive. In the sun-exposed areas of skin, there is marked thickening of the blood vessel walls in the papillary dermis. The blood vessels are surrounded by an eosinophilic, homogenized material that is periodic acid–Schiff-positive and diastase resistant (Figure 2 and Figure 3). Immunofluorescence studies have shown this material to be type IV collagen, consistent with reduplication of the perivascular basal lamina.3

Treatment consists of vigorous photoprotection, especially to UV-A radiation, as the protoporphyrin molecule photosensitizing affinity falls in the UV-A (400- to 410-nm) range. Patients should avoid sunlight, especially midday, whenever possible. Additional photoprotection should include use of UV-A–blocking sunscreens such as titanium oxide or zinc oxide.4 Protective clothing should also be worn. Since UV-A light is not filtered by ordinary window glass, patients are not fully protected even while indoors. Some florescent and incandescent indoor light sources also emit UV-A radiation and may cause problems for patients with EPP.

Beta-carotene (Solatene, Hoffman-LaRoche, Nutley, NJ), a natural constituent of several plant sources (ie, carrots, tomatoes, and oranges), has been used with benefit in patients with EPP. Cholestyramine may also encourage fecal protoporphyrin elimination.


AUTHOR INFORMATION

Accepted for publication April 1, 1997.

The opinions and assertions contained herein are the private ones of the authors and are not to be construed as official or reflecting the views of the Department of Defense or the US Army.

Corresponding author: MAJ Mary Mather, MC, USA, Dermatology Service, 1J, Walter Reed Army Medical Center, Washington, DC 20307.


REFERENCES

1. Hurwitz S. Clinical Pediatric Dermatology. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1993:98-99.
2. Poh-Fitzpatrick MB. The erythropoietic porphyrias. Dermatol Clin. 1986;2:291-296.
3. Murphy GM, Hawk JL, Magnus IA. Late-onset erythropoietic protoporphyria with unusual cutaneous features. Arch Dermatol. 1985;121:1309-1312. ABSTRACT
4. Harber LC, Bickers DR. Photosensitivity Diseases: Principles of Diagnosis and Treatment. 2nd ed. Toronto, Ontario: BC Decker Inc; 1989:254-263.

SECTION EDITOR: ENID GILBERT-BARNES, MD



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Possible Link Between Erythropoietic Protoporphyria and Alport Syndrome
Needles
Arch Pediatr Adolesc Med 1998;152:1248-1248.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1998 American Medical Association. All Rights Reserved.